Stockadora

8-K filings / November 20, 2026

Phio Pharmaceuticals Corp.: A stock exchange listing notice

Phio Pharmaceuticals Corp. filed a current report (Form 8-K) with the SEC on November 20, 2026. It reports a stock exchange listing notice.

Item 3.01

Stock exchange listing notice

  • Exchange Nasdaq From the filing
    Source
    “On November 16, 2026, Phio Pharmaceuticals Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying that the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum required pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
  • What it says The company does not meet a listing rule From the filing
    Source
    “On November 16, 2026, Phio Pharmaceuticals Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying that the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum required pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
  • Rule cited Nasdaq Listing Rule 5550(a)(2) From the filing
    Source
    “On November 16, 2026, Phio Pharmaceuticals Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying that the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum required pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
  • Notice date November 16, 2026 From the filing
    Source
    “On November 16, 2026, Phio Pharmaceuticals Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying that the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum required pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
    Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov

Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.